Sign up to save your podcasts
Or
Share Off-Target, On-Point: How Retrogenix® Reduces Risk and Animal Use
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Off-Target, On-Point: How Retrogenix® Reduces Risk and Animal Use
In this episode of Sounds of Science, learn how the Retrogenix® platform is reshaping drug development by identifying off-target risks earlier, reducing animal use, and gaining traction with regulators—now as part of the FDA’s ISTAND pilot program. Guests Nick Brown and Mark Aspinall-O’Dea from Charles River Discovery Services share real-world insights on their role in advancing NAMs and supporting safer, faster therapeutic development.
Show Notes
- Maximize Safer, Targeted Biologic Development with Smarter NAMs-Based Off-Target Screening
- Paving the Way for Enhanced Drug Development
- A Status Report on Cell-Based Protein Arrays
- Retrogenix® Human Protein Library
- Retrogenix®: The Screen Door of Drug Development
- Retrogenix® CAR Specificity Testing
- Charles River Launched New Retrogenix Non-Human Protein Library
View all episodes
By Charles River
4.7
1414 ratings
In this episode of Sounds of Science, learn how the Retrogenix® platform is reshaping drug development by identifying off-target risks earlier, reducing animal use, and gaining traction with regulators—now as part of the FDA’s ISTAND pilot program. Guests Nick Brown and Mark Aspinall-O’Dea from Charles River Discovery Services share real-world insights on their role in advancing NAMs and supporting safer, faster therapeutic development.
Show Notes
- Maximize Safer, Targeted Biologic Development with Smarter NAMs-Based Off-Target Screening
- Paving the Way for Enhanced Drug Development
- A Status Report on Cell-Based Protein Arrays
- Retrogenix® Human Protein Library
- Retrogenix®: The Screen Door of Drug Development
- Retrogenix® CAR Specificity Testing
- Charles River Launched New Retrogenix Non-Human Protein Library